Intrexon | XON - Pre Tax Profit


Intrexon reported $-60.48M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Agenus USD -10.61M 263.52M Dec/2025
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Amgen USD 3.92B 2.35B Sep/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.24B 117M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 389.94M 92.37M Dec/2025
Intrexon USD -60.48M 27.09M Jun/2024
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
Ligand Pharmaceuticals USD 141.14M 102M Sep/2025
MacroGenics USD -14.93M 31.75M Dec/2025
MannKind USD -20.93M 28.71M Dec/2025
Merck USD 6.74B 22M Sep/2025
Novartis USD 4.64B 445M Dec/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Thermo Fisher Scientific USD 2.12B 295M Dec/2025
Veracyte USD 40.63M 21.74M Dec/2025
Xencor USD -4.27M 1.76M Dec/2025